 |
|
September 4, 2010, 5:08 am
|
|
Home
|
10 stocks to watch in the week ahead
|
|
September 4th, 2010
|
|
Amgen, one of the world's biggest biotech companies, appears on an MSN Money list of recommended stocks. Here are StockScouter's top investment ideas.
|
|
Inflation, stagflation and you
|
|
September 4th, 2010
|
|
How can you navigate the threat of the 'flations'? One option is to follow the yellow brick road and buy gold.
|
|
6 outrageously overpriced products
|
|
September 4th, 2010
|
|
Some of these items are required (college textbooks); others just seem like they are (popcorn at the movies). The markups are astronomical.
|
|
Getting a yen for Japanese stocks
|
|
September 4th, 2010
|
|
Japan's currency keeps rising, making it a haven from US economic woes and creating bargains for investors. Here are 3 stocks to consider buying in the fall.
|
|
50 stocks to buy in September
|
|
September 4th, 2010
|
|
StockScouter, MSN Money's stock-picking tool, can help investors find companies capable of outperforming the broader market in the weeks ahead.
|
|
The 'Obama debt relief' scam
|
|
September 4th, 2010
|
|
New regulations will soon crack down on shady debt settlement companies. Until then, don't let desperation guide your decisions. Plus: What to ask before signing on.
|
|
Is that rental car really insured?
|
|
September 4th, 2010
|
|
The last thing you want on vacation is a costly surprise. Here are 3 ways to ensure you've got coverage.
|
|
The No. 1 key to a fund's success
|
|
September 4th, 2010
|
|
A study by Morningstar says the company's star rating system isn't the most vital factor in predicting a mutual fund's performance.
|
|
Featured Stories
|
|
|
Sick Investment Tools, Copyright © 2009, Sick Investment Tools LLC. All rights reserved. The content of this site may not be redistributed without the express written consent of
Sick Investment Tools. Individual editorials, articles and essays appearing on this site may be republished, but only with full attribution of both the author and Sick Investment Tools as well as a link to www.sickinvestmenttools.com. Your privacy is important to us—we will never rent or sell your e-mail or personal information. Please read our Privacy Policy.
No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein.
Sick Investment Tools does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. The publisher, editors and consultants of
Sick Investment Tools may actively trade in the investments discussed in this publication. They may have substantial positions in the securities recommended and may increase or decrease such positions without notice. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question.
|
|
|